Literature DB >> 2028562

Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.

E C de Boer1, W H de Jong, A P van der Meijden, P A Steerenberg, F Witjes, P D Vegt, F M Debruyne, E J Ruitenberg.   

Abstract

Cellular immunologic reactions occurring in the bladder after intravesical treatment with bacillus Calmette-Guérin (BCG) were investigated by flow cytofluorometric analysis of leukocytes present in the urine. Urine specimens from 11 superficial bladder cancer patients were collected before and 5, 24, 48 and 72 h after repeated BCG instillations. Monoclonal antibodies specific for granulocytes, monocytes/macrophages, and T-and B-lymphocytes were used to characterize and quantify leukocyte subpopulations. The total number of cells in urine was found to be 2- to 485-fold increased 24 h after BCG administration. The predominant cell type present was the polymorphonuclear granulocyte, probably representing a defense mechanism against mycobacteria. The main mononuclear leukocytes in urine specimens were monocytes/macrophages and T-lymphocytes, indicating an ongoing immune response in the bladder wall. Although percentages of lymphocytes were low, T- and B-cells could be identified using a selective cell measurement procedure. In conclusion, a clear increase in the numbers of granulocytes, monocytes/macrophages and T-lymphocytes in urine after intravesical BCG administration was demonstrated, indicating local activation of the immune system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2028562     DOI: 10.1007/bf00294021

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  15 in total

1.  Histopathology of BCG and thiotepa treated bladders.

Authors:  P Guinan; M Shaw; V Ray
Journal:  Urol Res       Date:  1986

2.  Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.

Authors:  E Huland; H Huland
Journal:  Cancer Res       Date:  1989-10-01       Impact factor: 12.701

3.  Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer.

Authors:  J M Lage; W C Bauer; D R Kelley; T L Ratliff; W J Catalona
Journal:  J Urol       Date:  1986-05       Impact factor: 7.450

Review 4.  Bacillus Calmette-Guérin as an anti-tumor agent. The interaction with cells of the mammalian immune system.

Authors:  M Davies
Journal:  Biochim Biophys Acta       Date:  1982-04-29

5.  Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

Authors:  W H De Jong; E C De Boer; A P Van der Meijden; P Vegt; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro.

Authors:  V B Antony; S A Sahn; A C Antony; J E Repine
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

7.  Human phagocytic cell responses to Mycobacterium leprae and Mycobacterium bovis Bacillus Calmette-Guérin. An in vitro comparison of leprosy vaccine components.

Authors:  T J Holzer; L Kizlaitis; M Vachula; C W Weaver; B R Andersen
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

8.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

9.  HLA-DR expression by high grade superficial bladder cancer treated with BCG.

Authors:  S Prescott; K James; A Busuttil; T B Hargreave; G D Chisholm; J F Smyth
Journal:  Br J Urol       Date:  1989-03

10.  Class I and class II HLA antigen expression by transitional cell carcinoma of the bladder: correlation with T-cell infiltration and BCG treatment.

Authors:  G F Stefanini; E Bercovich; V Mazzeo; W F Grigioni; E Emili; A D'Errico; M Lo Cigno; N Tamagnini; M Mazzetti
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

View more
  32 in total

Review 1.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

2.  Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.

Authors:  Y Luo; X Chen; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils.

Authors:  Mark P Simons; Jill M Moore; Troy J Kemp; Thomas S Griffith
Journal:  Infect Immun       Date:  2006-12-28       Impact factor: 3.441

4.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

Review 5.  Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.

Authors:  Sahdeo Prasad; Amit K Tyagi; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-24

6.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 7.  Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Yi Luo; Matthew J Knudson
Journal:  Clin Dev Immunol       Date:  2010-09-01

8.  BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis.

Authors:  Katja Schwarzer; Martin Foerster; Thomas Steiner; Inge-Marie Hermann; Eberhard Straube
Journal:  Cancer Cell Int       Date:  2010-06-29       Impact factor: 5.722

9.  Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

Authors:  M J Stassar; P D Vegt; P A Steerenberg; A P van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; W den Otter
Journal:  Urol Res       Date:  1994

Review 10.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.

Authors:  Chrysoula I Liakou; Sowmita Narayanan; Derek Ng Tang; Christopher J Logothetis; Padmanee Sharma
Journal:  Cancer Immun       Date:  2007-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.